Partial list of anticoagulants in development
| Agent . | Company . | Status, phase . |
|---|---|---|
| Direct thrombin inhibitors | ||
| Dabigatran etexilate | Boehringer Ingelheim | 3 |
| AZD0837 | Astra Zeneca | 2 |
| MCC 977 | Mitsubishi Pharma | 2 |
| Direct factor Xa inhibitors | ||
| Rivaroxaban | Bayer, Ortho-McNeill | 3 |
| Apixaban | Bristol-Myers Squibb, Pfizer | 3 |
| Betrixaban | Portola | 2 |
| YM150 | Astellas | 2 |
| Edoxaban (DU-176b) | Daichi Sankyo | 3 |
| TAK-442 | Takeda | 2 |
| Otamixaban* | Sanofi-Aventis | 2 |
| Indirect factor Xa inhibitor | ||
| Idraparinux* | Sanofi-Aventis | 3 |
| Idrabiotaparinux* | Sanofi-Aventis | 3 |
| Novel VKA | ||
| ATI-5923 | Aryx Therapeutics | 2b |
| Agent . | Company . | Status, phase . |
|---|---|---|
| Direct thrombin inhibitors | ||
| Dabigatran etexilate | Boehringer Ingelheim | 3 |
| AZD0837 | Astra Zeneca | 2 |
| MCC 977 | Mitsubishi Pharma | 2 |
| Direct factor Xa inhibitors | ||
| Rivaroxaban | Bayer, Ortho-McNeill | 3 |
| Apixaban | Bristol-Myers Squibb, Pfizer | 3 |
| Betrixaban | Portola | 2 |
| YM150 | Astellas | 2 |
| Edoxaban (DU-176b) | Daichi Sankyo | 3 |
| TAK-442 | Takeda | 2 |
| Otamixaban* | Sanofi-Aventis | 2 |
| Indirect factor Xa inhibitor | ||
| Idraparinux* | Sanofi-Aventis | 3 |
| Idrabiotaparinux* | Sanofi-Aventis | 3 |
| Novel VKA | ||
| ATI-5923 | Aryx Therapeutics | 2b |
Parenteral agent.